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Curcumin enhances the cytotoxic and chemosensitising effects of lenalidomide 
in human multiple myeloma cells 
Abstract 
Background: Curcumin, the active component of the Curcuma longa plant, has been shown to potentiate 
the effect of the immunomodulatory drugs (IMiDs) thalidomide and Bortezomib against human myeloma 
cell lines and a nude mice model. Its effect on the other IMid, lenalidomide, has not been evaluated. This 
study aims to investigate the mechanism of action of curcumin and its potential ability to positively 
interact with lenalidomide. Method: we designed an in-vitro study to investigate the cytotoxic and chemo-
sensitising effects of curcumin alone and in combination with lenalidomide on the human myeloma H929 
cell line. Results: Incubation of H929 cells with curcumin (30mM) or lenalidomide (2.5 mM) for 3 days 
resulted in 26.35% (±1.06) and 30.81%(±2.98) apoptotic cells respectively. When 30 mM curcumin was 
combined with 2.5 mM lenalidomide, 50.4% (±3.37) apoptotic cells were detected by flow cytometry and 
the increase was significant compared to either curcumin alone or lenalidomide alone (anova p = 0.0026). 
Furthermore, gene analysis studies show that curcumin enhances the cytotoxic effect of lenalidomide via 
suppression of the cereblon and multi-drug resistant genes. Conclusion: Curcumin exerts a cytotoxic 
effect additive to that of lenalidomide on H929 myeloma cells, and it also enhances the chemo-
sensitizing effects of this agent. 
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Abstract  
Background: Curcumin, the active component of the Curcuma longa plant, has been shown to potentiate the effect of the 
immunomodulatory drugs (IMiDs) thalidomide and Bortezomib against human myeloma cell lines and a nude mice model.  
Its effect on the other IMid, lenalidomide, has not been evaluated. This study aims to investigate the mechanism of action 
of curcumin and its potential ability to positively interact with lenalidomide.  
Method: we designed an in-vitro study to investigate the cytotoxic and chemo-sensitising effects of curcumin alone and in 
combination with lenalidomide on the human myeloma H929 cell line. 
Results: Incubation of H929 cells with curcumin (30M) or lenalidomide (2.5 mM) for 3 days resulted in 26.35% (±1.06) 
and 30.81%(±2.98) apoptotic cells respectively. When 30 M curcumin was combined with 2.5 mM lenalidomide, 50.4% 
(±3.37) apoptotic cells were detected by flow cytometry and the increase was significant compared to either curcumin 
alone or lenalidomide alone (anova p = 0.0026). Furthermore, gene analysis studies show that curcumin enhances the 
cytotoxic effect of lenalidomide via suppression of the cereblon and multi-drug resistant genes. 
Conclusion: Curcumin exerts a cytotoxic effect additive to that of lenalidomide on H929 myeloma cells, and it also 
enhances the chemo-sensitizing effects of this agent.  
Key words 
Lenalidomide, Curcumin, Multiple myeloma cells, In-vitro 
1 Introduction 
Current treatment options for patients with multiple myeloma include the use of a combination of cytotoxic drugs and 
immunomodulatory drugs (IMiDs) such as thalidomide, lenalidomide, bortezomib and pomalidomide [1, 2]. IMiDs have 
been shown to have anti-inflammatory, anti-angiogenic, pro-apoptotic and immunomodulatory properties [3, 4]. Despite 
www.sciedu.ca/jhm                                                                                                Journal of Hematological Malignancies, 2013, Vol. 3, No.2 
ISSN 1925-4024   E-ISSN 1925-4032 2
their therapeutic potential, only 80% of patients with myeloma respond to IMiDs-based therapy [1]. Factors which 
determine response to IMiDs have not been clearly defined.  
Curcumin, the active component of the Curcuma longa plant, displays a wide range of biological activities including 
anti-oxidant, anti-inflammatory and cytotoxicity to numerous cancer cell types [5]. Its anti-cancer effect has been attributed 
to regulation of multiple cell signalling pathways involved in cell proliferation and apoptosis [6]. In vitro and in vivo studies  
have shown that curcumin inhibits activation of nuclear factor-kappa B (NF-kappa B), a transcription factor closely linked 
to chemoresistance , in various types of haematological as well as non-haematological cancers [7-9]. Sung et al [10] have 
shown that curcumin can circumvent chemoresistance in vitro and potentiate the effect of thalidomide and bortezomib 
against human multiple myeloma in a nude mouse model. Bai & Zhang [11] have shown that curcumin enhances the 
cytotoxic effects of bortezomib in a human multiple myeloma cell line.  
Recent clinical studies have demonstrated that oral administration of curcumin, even at high doses, is well tolerated and 
can decrease the paraprotein load, free light chains, bone turnover and % plasma cell infiltrate into the bone marrow in 
some patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma 
(SMM) [12-15]. 
Given that both curcumin and IMiDs have demonstrated pro-apoptotic and chemo-sensitising properties, we designed an 
in-vitro study to investigate the cytotoxic and chemo-sensitising effects of curcumin alone and in combination with 
lenalidomide on the human myeloma cell line H929.  
2 Materials and methods 
2.1 Cell culture 
The human myeloma cell line H929 was obtained from the ATCC and maintained in RPMI 1640 medium supplemented 
with 10% fetal bovine serum (FBS), penicillin (100U/ml) and streptomycin (100ug/ml) at 37oC in an atmosphere of 5% 
CO2.  
Curcumin (C3 complex from Sabinsa Corporation, Piscataway, NJ, containing 3 curcuminoids ie curcumin, desme- 
thoxycurcumin and bisdesmethoxycurcumin) was dissolved in DMSO at 1mM as a stock solution and stored at -20oC. 
Lenalidomide was dissolved in DMSO (Dimethylsulfoxide) at 200 mM as a stock solution and stored at -20oC. For in vitro 
use, dilutions of the stock solutions were made in culture medium, and filter sterilised. The maximum concentration of 
DMSO in the culture medium (1%) had no effect on cell death of H929 cells. 
2.2 Evaluation of apoptosis 
Cells treated with curcumin and/or lenalidomide were cultured for 3 days before they were analysed for apoptosis using 
the Annexin V-FITC kit (Miltenyi Biotech). One million cells were washed and resuspended in binding buffer and stained 
with 10µl of Annexin V-FITC for 15 minutes at room temperature in the dark. The cells were washed once with 1 ml of 
binding buffer and resuspended in 500µl of binding buffer. Five microliter of propidium iodide (PI) solution (provided) 
was added immediately prior to analysis by flow cytometry.  
2.3 Sample preparation and real-time PCR 
All cells used for real-time PCR analysis were cultured under the same conditions as those for evaluation of apoptosis, 
however the culture period was 2 instead of 3 days. Total RNA was extracted from the cells using the RNeasy mini kit 
(Qiagen, Melbourne, Australia), followed by complimentary DNA (cDNA) synthesis using the Superscript III first strand 
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3.3 Effect of curcumin and lenalidomide on multi-drug resistant genes 
The expression of genes associated with multidrug resistance (MDR) in multiple myeloma, MDR1 (p-gp) and the MDR 
protein (MRP), were analysed by real time RT-PCR. Treatment of H929 cells with either  of curcumin or 2.5 mM of 
lenalidomide for 48 hours decreased the expression of MDR compared to untreated cells. There was a 4-fold reduction of 
MDR mRNA expression as a result of curcumin treatment, while in the lenalidomide-treated cells there was a 2-fold 
reduction of MDR mRNA expression compared to the untreated controls. A combination of the two agents resulted in a 
3-fold reduction in the mRNA expression of the MDR gene (see Figure 3). 
MRP mRNA expression decreased by 2 and 1.5-fold respectively after incubating the cells with either curcumin or 
lenalidomide as compared to untreated controls. Enhanced reduction of MRP mRNA expression was observed when cells 
were treated with a combination of both agents. An approximate 4-fold reduction in the MRP mRNA level was evident 
compared to the untreated controls (see Figure 3). 
4 Discussion 
This study demonstrates that both curcumin and lenalidomide exert a cytotoxic effect on H929 myeloma cells resulting in 
apoptosis.  Furthermore, the combination of curcumin and lenalidomide enhances apoptosis of these cells.  These findings 
are similar to those of previous studies with myeloma cell lines (U266 and H929) using curcumin and a less potent 
immunomodulatory drug, i.e. thalidomide [10] and bortezomib [11] respectively. The H929 cell line was chosen for this 
study because it harbours the t(4; 14) translocation, whereas the U266 cell line carries a t(11; 14) translocation [18]. Patients 
that carry the t(11; 14) translocation are considered “low risk”, while those harbouring the t(4; 14) translocation are 
associated with a poor prognosis that is only partially improved by the use of lenalidomide [19]. The lack of response in 
patients with t(4; 14) probably explains our in vitro observation that the H929 cells were only partially responsive to 
lenalidomide which reached a plateau at 3mM. 
Recent studies have demonstrated that the cereblon (CRBN) gene is a primary target for IMiD drugs like thalidomide and 
lenalidomide [17]. Exposure of myeloma cells to lenalidomide results in cell death, and this cytotoxic effect is accompanied 
by suppression of the CRBN gene [17]. Since a combination of curcumin and lenalidomide resulted in an increased 
apoptotic effect in this study, we sought to analyse if this cytotoxicity might be related to a change in the gene expression 
of CRBN mRNA. Our results confirm that mRNA expression of CRBN is similarly reduced in the presence of either 
curcumin or lenalidomide as compared to untreated controls and the reduction is almost doubled when the two agents were 
used in combination. These findings indicate that curcumin can enhance the cytotoxic effect of lenalidomide via 
suppression of the cereblon gene. 
Multidrug resistance is a significant factor that contributes to the success or failure of chemotherapy in various types of 
cancer including multiple myeloma. Myeloma patients often show resistance to a number of cytotoxic drugs once they 
develop resistance to doxorubicin-based chemotherapy [20]. Here, we also examined the effect of curcumin and 
lenalidomide as single agents and in combination on the expression of two common multidrug resistant genes, the MDR1, 
encoding the P-glycoprotein, and the MRP gene which encodes the multidrug resistant protein. As single agents, both 
curcumin and lenalidomide reduced the expression of both MDR1 and MRP. A combination of both agents resulted in 
enhanced reduction of MRP expression. This observation has not been previously reported. 
 Exposure of H929 cells to curcumin alone resulted in a greater reduction in MDR1 compared to lenalidomide alone or a 
combination of both agents. Chen et al [21] report that lenalidomide is not a P-gp inhibitor in vitro or in vivo. This may 
explain the greater MDR1 response to curcumin than lenalidomide inH929 cells.  Curcumin has also been shown to reduce 
MDR1 gene expression in primary cells isolated from newly diagnosed and relapsed leukaemia patients [22]. 
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About one third of patients with relapsed or refractory myeloma respond to thalidomide-containing treatment, and this 
response rate improves to 60% with a lenalidomide-containing regimen [23]. Lenalidomide-containing therapy also has the 
added advantage of overcoming resistance to both conventional chemotherapy and to thalidomide [24, 25]. A recent review 
by Quach et al [4] refers to the future optimization of lenalidomide’s use in combination with other therapeutic agents. 
Curcumin-induced inhibition of NF-kB, which results in decreased transcription of various cytokines, could potentially 
augment lenalidomide’s ability to disrupt bone marrow stromal support for multiple myeloma cells. Our findings and 
those of Sung et al [10] suggest that curcumin can potentiate not only the cytotoxic effect of lenalidomide or thalidomide, 
but also enhance the chemo-sensitising effects of these agents. The clinical implications arising from these observations 
are two pronged: i) curcumin studies can be designed to assess the additive effects of curcumin to the current treatment 
protocols such as MPR (melphalan-prednisolone-lenalidomide[4]) and Len-Dex (lenalidomide-dexamethasone[4]) and ii) 
curcumin may be used as an alternative to corticosteroids in such protocols.  
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